{
    "organizations": [],
    "uuid": "a685375bd33207f9eadb2a0b33c7a4b13b52ee50",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-summit-therapeutics-announces-anal/brief-summit-therapeutics-announces-analysis-showing-ezutromid-significantly-reduced-muscle-inflammation-in-phase-2-clinical-trial-idUSFWN1QG0T9",
    "ord_in_thread": 0,
    "title": "BRIEF-Summit Therapeutics ‍Announces Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation In Phase 2 Clinical Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Summit Therapeutics Plc:\n* ‍ANNOUNCES NEW ANALYSIS SHOWING EZUTROMID SIGNIFICANTLY REDUCED MUSCLE INFLAMMATION IN PHASE 2 CLINICAL TRIAL IN DMD​\n* ‍MRS-T2 DATA PROVIDE EVIDENCE OF EARLY IMPACT OF EZUTROMID ON DOWNSTREAM MUSCLE HEALTH​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-26T20:07:00.000+02:00",
    "crawled": "2018-02-27T15:08:06.070+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "summit",
        "therapeutic",
        "plc",
        "new",
        "analysis",
        "showing",
        "ezutromid",
        "significantly",
        "reduced",
        "muscle",
        "inflammation",
        "phase",
        "clinical",
        "trial",
        "data",
        "provide",
        "evidence",
        "early",
        "impact",
        "ezutromid",
        "downstream",
        "muscle",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}